Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MASE-T in Metastatic Melanoma
NCT04904185Phase 1Terminated
- Start
- Sep 2021
- Primary completion
- Jun 2024
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of TAA-T in melanoma (2 arms). Primary endpoints: Tolerability of the Treatment up to 2.8 years, Number of Patients Excluded Due to Feasibility Issues up to 2.8 years and 1 more. Started Sep 2021; status: terminated.
02
Drugs
TAA-T
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04904185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04904185.